Pharmacological Treatment for Paroxysmal Sympathetic Hyperactivity | Zendy

Elizabeth A. Shald | Zendy; Jacob A. Reeder | Zendy; Michael Finnick | Zendy; Ishani Patel | Zendy; Kyle Evans | Zendy; Rebecca K. Faber | Zendy; Brian W. Gilbert | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacological Treatment for Paroxysmal Sympathetic Hyperactivity

Author(s) -

Elizabeth A. Shald,

Jacob A. Reeder,

Michael Finnick,

Ishani Patel,

Kyle Evans,

Rebecca K. Faber,

Brian W. Gilbert

Publication year - 2020

Publication title -

critical care nurse

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.342

H-Index - 44

eISSN - 1940-8250

pISSN - 0279-5442

DOI - 10.4037/ccn2020348

Subject(s) - medicine , sympathetic activity , medline , intensive care medicine , cardiology , heart rate , political science , blood pressure , law

Paroxysmal sympathetic hyperactivity, which affects up to 10% of all acquired brain injury survivors, is characterized by elevated heart rate, blood pressure, respiratory rate, and temperature; diaphoresis; and increased posturing. Pharmacological agents that have been studied in the management of this disorder include opiates, γ-aminobutyric acid agents, dopaminergic agents, and β blockers. Although paroxysmal sympathetic hyperactivity is a relatively common complication after acquired brain injury, there is a paucity of recommendations or comparisons of agents for the management of this disorder.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research